Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study
Authors' conclusion
Our results may indicate that individuals have diverse experiences of side effects, allowing the global index to capture these variations, even when they differ across patients.
Study context
- Population
- Patients with rheumatoid arthritis (RA) reporting symptomatic side effects of RA medications
- Participants
- 560 patients
- Outcome
- Construct validity of the single-item bother measure (Functional Assessment of Chronic Illness Therapy (FACIT) GP5) vs current symptomatic side effects (Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PROCTCAE))
Methodological detailsweb-based survey, multiple correspondence analysis
- Web-based survey
- Multiple correspondence analysis
Main finding
As reported in the abstract
Dimensions of 80 symptomatic side effects (multiple correspondence analysis (MCA))
- Clear elbow point after the first dimension; one dimension captured the most meaningful information
- Overall side effect burden score reflected a broad concept influenced by a variety of symptomatic side effects, each with only a negligible to weak impact
Observational data: associations, not effects.
Original publication
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study. Semin Arthritis Rheum. Published 19 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →